Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

Delayed Quote. Delayed  - 07/29 05:30:49 pm
80.3 CHF   --.--%
07/27DJAmgen Profit Rises 13%, 2016 Outlook Raised
07/27DJGLAXOSMITHKLINE : Helped and Hurt by Sterling's Post-Brexit Fall
07/27 NOVARTIS : Guidepost Solutions Appoints Sokolow Former Novartis Serv..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
Latest news on NOVARTIS AG
06/22 NOVARTIS : Timely use of Novartis' Entresto could prevent or postpone over 28,00..
06/22 NOVARTIS : Next-generation antimalarial treatment
06/21 NOVARTIS : CSC professor cycling to Kearney for Sandoz meeting
06/21 NOVARTIS : "Pure Nebraska" segments filmed at Sandoz Center
06/20 Novartis aims to triple biosimilar drugs by 2020
06/20 NOVARTIS : Reigniting the malaria fight
06/18 NOVARTIS : New treatment to tackle cataracts, ophthalmology head says
06/16 NOVARTIS : data show more than 50 percent of eligible Ph+ CML patients maintain ..
06/16 NOVARTIS : Institute for Biomedical Research Details Findings in Chemical Biolog..
06/16 NOVARTIS : Patent Issued for JAK PI3K/MTOR Combination Therapy (USPTO 9358229)
06/16 NOVARTIS : Patent Issued for Method of Treating a Lens Forming Surface of at Lea..
06/16 NOVARTIS : pivotal data for Tafinlar« + Mekinist« demonstrated a 63 percent over..
06/16 NOVARTIS : Expands Partnership with Medicines for Malaria Venture to Develop Nex..
06/15 NOVARTIS : and MMV expand partnership to develop KAF156
06/15 NOVARTIS : étend son partenariat avec Medicines for Malaria Venture pour dévelop..
06/15 NOVARTIS : expands partnership with Medicines for Malaria Venture to develop nex..
06/15 NOVARTIS : expands partnership with Medicines for Malaria Venture to develop nex..
06/13 GOOD PHARMA : How Marketing creates Value in Pharma
06/10 NOVARTIS : Colombia to force Novartis to lower prices of cancer drug
06/10 NOVARTIS : Long-term safety data for Revolade in adults with chronic ITP
06/10 NOVARTIS : highlights long-term safety data of Revolade« in adults with chronic ..
06/10 NOVARTIS : presents data showing Jakavi« is superior to best available therapy i..
06/09 NOVARTIS : Colombia to force Novartis to lower prices of cancer drug
06/09 NOVARTIS : Trademark Application for "SEE LOOK FEEL" Filed by Novartis AG
06/09 NOVARTIS : Patent Issued for Biomarkers for IAP Inhibitor Therapy (USPTO 9353419..
06/09 EISAI : Enters into a Collaboration Agreement to Co-Promote LENVIMA« Lenvatinib ..
06/09 NOVARTIS : announces US collaboration to co-promote Lenvima« in combination with..
06/09 JOHNSON & JOHNSON : Industry weighs radical shake-up of European drug pricing
06/09 NOVARTIS : Mereo Biopharma Shares Up 22% As It Starts Trading On AIM (ALLIPO)
06/09 NOVARTIS : New data demonstrates Sandoz' etanercept and rituximab biosimilar can..
06/08 NOVARTIS : announces AMG 334 significantly reduces patients' monthly migraine da..
06/08 NOVARTIS : presents new scientific evidence for Cosentyx in ankylosing spondylit..
06/07 NOVARTIS : combination therapy Tafinlar + Mekinist demonstrates overall survival..
06/07 56 key drugs set to get cheaper
06/07 NOVARTIS : Sandoz Canada Is Committed to Maintain a Supply of Injectable Medicin..
06/06 NOVARTIS : combination therapy Tafinlar« + Mekinist« demonstrates overall surviv..
06/06 NOVARTIS : pivotal data for Tafinlar« + Mekinist« demonstrated a 63 percent over..
06/06 NOVARTIS : data show more than 50 percent of eligible Ph+ CML patients maintain ..
06/06DJNOVARTIS : Mereo BioPharma to Trade on AIM -- Update
06/06 NOVARTIS : Mereo BioPharma Raises GBP14.8 Million Ahead Of AIM Admission (ALLIPO..
06/06 NOVARTIS : British biopharma start-up Mereo to list in London
06/04 NOVARTIS : data show more than 50 percent of eligible Ph+ CML patients maintain ..
06/04 NOVARTIS : data show more than 50 percent of eligible Ph+ CML patients maintain ..
06/04 NOVARTIS : Hood's fear of loss of $30M allayed
06/03 NOVARTIS : Alcon Research Assigned Patent
06/03 NOVARTIS : Lexington Christian Academy Students Take a Look Behind the Lens
06/02 NOVARTIS : "Combination of a Phosphatidylinositol-3-Kinase (Pi3k) Inhibitor and ..
06/02 NOVARTIS : Patent Issued for Devices, Systems and Methods for Posterior Segment ..
06/02 NOVARTIS : Researchers Submit Patent Application, "Combination Therapy Comprisin..
06/02 NOVARTIS : drug Afinitor« receives EU approval to treat certain types of advance..
06/02 NOVARTIS : Korea embroiled in legal trouble
06/01 NOVARTIS : Foundation Convenes Experts to Examine the Promise and Practicality o..
06/01 SUN PHARMACEUTICAL : Pharma projects 8% revenue growth for fy17
05/27 Novartis, Foundation Medicine, Celgene Invest in Healthcare Informatics Firm ..
05/27 CATALENT : Strengthens Leadership Position in Asia-Pacific with Key Appointments..
05/27 NOVARTIS : Board okays buyback
05/26 Anacor received rival bid before Pfizer deal - filing
05/26 CATALENT : Strengthens Leadership Position in Asia-Pacific with Key Appointments..
05/26 NOVARTIS : Creating the sights and sounds
05/25 NOVARTIS : highlights its strong foundation for long-term, sustainable growth at..
05/25 NOVARTIS : highlights its strong foundation for long-term, sustainable growth at..
05/24 NOVARTIS : Sandoz' biosimilar rituximab regulatory submission accepted by Europe..
05/23 NOVARTIS' : Entresto given strong Class I recommendation in both US and EU heart..
05/22 NOVARTIS : New cancer drug on NHS
05/21 NOVARTIS' : Entresto« given strong Class I recommendation in both US and EU hear..
05/21 NOVARTIS : ' Entresto« given strong Class I recommendation in both US and EU hea..
05/20DJNOVARTIS : Colombia Threatens to Override Novartis's Patent on Gleevec
05/20DJNOVARTIS : Colombia Threatens to Override Novartis's Patent on Gleevec
05/20 NOVARTIS : announces investment in FortiHFy clinical program of Entresto and hea..
05/20 NOVARTIS : Alcon Research Assigned Patent
05/19 NOVARTIS : "Pharmaceutical Combinations of a Pi3k Inhibitor and a Microtubule De..
05/19 NOVARTIS : Patent Issued for Combination of Somatostatin-Analogs with 11beta-Hyd..
05/19 Colombia battles world's biggest drugmaker over cost of cancer medicine
05/19 NOVARTIS : announces investment in FortiHFy clinical program of Entresto« and he..
05/19 NOVARTIS : A hive of industry with a buzz of volunteering
Prev.1   2  3  4  5  6  7  8  9  10Next
Advertisement
Financials ($)
Sales 2016 48 844 M
EBIT 2016 11 451 M
Net income 2016 7 496 M
Debt 2016 14 565 M
Yield 2016 3,42%
P/E ratio 2016 24,24
P/E ratio 2017 22,02
EV / Sales 2016 4,70x
EV / Sales 2017 4,55x
Capitalization 215 109 M
More Financials
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 89,8 $
Spread / Average Target 8,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-5.30%215 109
JOHNSON & JOHNSON21.91%344 463
PFIZER INC.14.28%223 732
ROCHE HOLDING LTD.-9.99%218 231
MERCK & CO., INC.11.06%162 372
BRISTOL-MYERS SQUIBB C..8.75%124 997
More Results